APO 010

Drug Profile

APO 010

Alternative Names: APO-010

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apoxis
  • Developer Oncology Venture; Onxeo SA
  • Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 26 Jun 2018 2X Oncology is now called Oncology Venture US
  • 31 May 2017 Phase-I/II clinical trials in Multiple myeloma (Metastatic disease, Second-line therapy or greater) in Denmark (IV)
  • 21 Mar 2017 Preclinical trials in Multiple myeloma in Denmark prior to March 2017 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top